Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Bron – page 9

478 clinical trials in Bron, France across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Bron at a glance
478
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

478 trials in Bron

Open in trial search

Small intestine neuroendocrine tumour

Recruiting

Study on Reducing Side Effects of Lutetium (177Lu) Oxodotreotide in Patients with Advanced Midgut Neuroendocrine Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177LU) oxodotreotide
  • Sponsor:Grupo Espanol De Tumores Neuroendocrinos

Non-small cell lung cancer stage III

Recruiting

Study on the Effectiveness of Cemiplimab, Carboplatin, and Paclitaxel for Unfit or Elderly Patients with Unresectable Stage III Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Prostate cancer metastatic

Recruiting

Study on Re-treatment with Lutetium (177Lu) Vipivotide Tetraxetan for Men with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide
  • Sponsor:Hospices Civils De Lyon

Cognitive disorder

Recruiting

Study on Lithium Carbonate for Patients with TBR1-Related Neurocognitive Disorder

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lithium Carbonate
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Meningioma

Recruiting

Study of Lutetium (177Lu) Oxodotreotide for Patients with Recurrent Meningioma Without Surgery or Radiotherapy Options

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Nervous system disorder

Recruiting

Study on the Physical Impact of Multiple Sclerosis and Continued Access to Ocrelizumab for Patients Previously in a Related Study

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Juvenile idiopathic arthritis

Recruiting

Study of Sarilumab for Children and Adolescents with Systemic Juvenile Idiopathic Arthritis (sJIA)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Sarilumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Non-small cell lung cancer

Recruiting

Study of Repotrectinib for Frail or Elderly Patients with Advanced Non-Small Cell Lung Cancer with ROS1 Gene Rearrangement

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Repotrectinib
  • Sponsor:Centre Hospitalier Intercommunal Toulon / La Seine-Sur-Mer

Cardiogenic shock

Recruiting

Study on the Early Use of Levosimendan Compared to Placebo for Patients with Cardiogenic Shock

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ascorbic Acid
  • Sponsor:CHRU De Nancy

Von Willebrand's disease

Recruiting

Study on Preventing Bleeding in Children with Severe von Willebrand Disease Using Vonicog Alfa and Octocog Alfa

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Octocog Alfa
  • Sponsor:Takeda Development Center Americas Inc.

Parkinson's disease

Recruiting

Study on Amantadine for Reducing Motor Fluctuations in Advanced Parkinson's Disease Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amantadine Hydrochloride
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Squamous cell carcinoma of lung+2

Recruiting

Study Comparing OSE2101 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Immunotherapy Resistance

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:OSE Immunotherapeutics

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Bron

What the registry says about research in the country

01 Neurological Disorders

Innovative research focusing on multiple sclerosis and Parkinson's disease, including advanced PET imaging studies and evaluation of novel therapeutic approaches.

  • Multiple Sclerosis Imaging
  • Parkinson's Disease Treatment
  • Essential Tremor Studies

Studies include neuroinflammation assessment and serotonergic receptor expression analysis.

02 Brain Tumors

Comprehensive research into glioblastoma treatment approaches, combining innovative therapies with standard protocols.

  • Newly Diagnosed Glioblastoma
  • Nanoparticle Therapy
  • Combined Treatment Approaches

Integration of radiotherapy, chemotherapy, and novel therapeutic agents for improved patient outcomes.

03 Rare Diseases

Targeted research on rare conditions including Dravet Syndrome and Alagille syndrome, focusing on innovative therapeutic approaches.

  • Hereditary Conditions
  • Genetic Disorders
  • Novel Treatment Evaluation

Emphasis on developing effective treatments for previously undertreated rare conditions.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.